Literature DB >> 20571464

The pharmacogenetics of calcineurin inhibitor-related nephrotoxicity.

Dennis A Hesselink1, Rachida Bouamar, Teun van Gelder.   

Abstract

Chronic calcineurin inhibitor (CNI)-induced nephrotoxicity is associated with prolonged use of cyclosporine and tacrolimus and has been observed after all types of transplantation, as well as during treatment of autoimmune disease. Extensive alterations in the renal architecture including glomerular sclerosis, tubular atrophy and interstitial fibrosis may lead to end-stage renal failure. Increasing evidence shows that pharmacogenetic factors explain part of the between-patient differences in susceptibility to developing CNI-induced nephrotoxicity. In this paper this evidence is reviewed, with special emphasis on the role of genetic factors influencing metabolism and transportation of CNIs in both acceptor and donor.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20571464     DOI: 10.1097/FTD.0b013e3181e44244

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  18 in total

1.  Genetic Variants Associated With Immunosuppressant Pharmacokinetics and Adverse Effects in the DeKAF Genomics Genome-wide Association Studies.

Authors:  William S Oetting; Baolin Wu; David P Schladt; Weihua Guan; Jessica van Setten; Brendan J Keating; David Iklé; Rory P Remmel; Casey R Dorr; Roslyn B Mannon; Arthur J Matas; Ajay K Israni; Pamala A Jacobson
Journal:  Transplantation       Date:  2019-06       Impact factor: 4.939

Review 2.  Clinical implementation of pharmacogenetics in kidney transplantation: calcineurin inhibitors in the starting blocks.

Authors:  Laure Elens; Rachida Bouamar; Nauras Shuker; Dennis A Hesselink; Teun van Gelder; Ron H N van Schaik
Journal:  Br J Clin Pharmacol       Date:  2014-04       Impact factor: 4.335

Review 3.  The influence of pharmacogenetics and cofactors on clinical outcomes in kidney transplantation.

Authors:  Nicolas Picard; Pierre Marquet
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-03-25       Impact factor: 4.481

4.  Long-term therapeutic effects and safety of tacrolimus added to methotrexate in patients with rheumatoid arthritis.

Authors:  Takeyuki Kanzaki; Kimito Kawahata; Hiroko Kanda; Keishi Fujio; Kanae Kubo; Lisa Akahira; Kazuya Michishita; Toshiki Eri; Kazuhiko Yamamoto
Journal:  Rheumatol Int       Date:  2012-07-18       Impact factor: 2.631

Review 5.  Pharmacogenetics and immunosuppressive drugs in solid organ transplantation.

Authors:  Teun van Gelder; Ron H van Schaik; Dennis A Hesselink
Journal:  Nat Rev Nephrol       Date:  2014-09-23       Impact factor: 28.314

Review 6.  Molecular and clinical aspects of drug-induced gingival overgrowth.

Authors:  P C Trackman; A Kantarci
Journal:  J Dent Res       Date:  2015-02-13       Impact factor: 6.116

Review 7.  Systemic cyclosporine and corneal transplantation.

Authors:  Mohammed Ziaei; Fatemeh Ziaei; Bita Manzouri
Journal:  Int Ophthalmol       Date:  2016-02       Impact factor: 2.031

8.  Genetic and clinical determinants of early, acute calcineurin inhibitor-related nephrotoxicity: results from a kidney transplant consortium.

Authors:  Pamala A Jacobson; David Schladt; Ajay Israni; William S Oetting; Yi Cheng Lin; Robert Leduc; Weihau Guan; Vishal Lamba; Arthur J Matas
Journal:  Transplantation       Date:  2012-03-27       Impact factor: 4.939

Review 9.  The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation.

Authors:  Dennis A Hesselink; Rachida Bouamar; Laure Elens; Ron H N van Schaik; Teun van Gelder
Journal:  Clin Pharmacokinet       Date:  2014-02       Impact factor: 6.447

Review 10.  Pharmacogenetics in kidney transplantation: recent updates and potential clinical applications.

Authors:  Laure Elens; Dennis A Hesselink; Ron H N van Schaik; Teun van Gelder
Journal:  Mol Diagn Ther       Date:  2012-12       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.